Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANCHOR phase 3 trial of MK-1406 for influenza prevention in high-risk adults and adolescents
jRCT2031260425Phase 3Recruiting
- Sponsor
- Cidara Therapeutics
- Start
- Oct 2026
- Modality
- Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in influenza comparing MK-1406 with Placebo (2 arms). Primary endpoint: Percentage of participants experiencing protocol-defined influenza-like illness occurring 7 days or more after and up to 24 weeks after administration of study drug. Started Oct 2026; status: recruiting.
02
Drugs
retezrelvir
03
Conditions
influenza
Beyond the preview
Go deeper on jRCT2031260425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260425.